Sanofi to sell 51% stake in Opella
Sanofi in exclusive talks with CD&R over sale of $17 billion Opella
By Dominique Patton PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).
Sanofi Enters Exclusive Negotiations To Sell 50% Stake In Opella To CD&R
Sanofi (SNYNF) announced it has entered into exclusive negotiations to sell a 50 percent controlling stake in its consumer healthcare
Sanofi to sell CD&R 50% controlling stake in Opella
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R).
Sanofi Sells Controlling Stake in Opella to CD&R with Job Guarantees
CD&R is nearing a deal to acquire control of Sanofi’s consumer health unit after it signed social commitments with the French government.
Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI, Reuters reports
France will take a stake in Sanofi’s Opella through the Public Investment Bank, or BPI, finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro
Sanofi Enters Exclusive Talks With CD&R Over Opella Stake Sale
Sanofi entered into exclusive talks to sell a controlling stake in its consumer-healthcare business Opella to Clayton Dubilier & Rice in a deal that values the business as a whole at 16 billion euros ($17.
Sanofi, CD&R in Exclusive Negotiations for Sale, Purchase of 50% Stake in Opella
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
Sanofi enters exclusive talks with CD&R for Opella sale
Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R). The French pharmceutical company said its Opella business has been valued at around 16 billion euros ($17.
cnbctv1810m
Sanofi to sell 50% of Opella in $17 billion deal with CD&R, job guarantees for France included
Sanofi, which is joining a growing number of drugmakers shedding consumer related businesses, said Opella had been valued at ...
Sanofi Pursues Sale Of Painkiller After Political Controversy
Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...
Politico Europe1h
Paris threatens millions in penalties if paracetamol-maker leaves France after US takeover
Under the trilateral deal signed by Sanofi, CD&R and the government, Opella will have to pay a €40 million penalty if it ...
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant ...
EuropaWire1h
Sanofi and CD&R Join Forces to Propel Opella’s Global Consumer Healthcare Expansion
Sanofi and CD&R have entered exclusive negotiations for CD&R to acquire a 50% controlling stake in Opella, Sanofi’s consumer ...
PharmiWeb4h
Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer ...
France says it has received assurances over sale of painkiller maker to US investment fund CD&R
The proposed sale turned into a real political issue because Opella's products include Doliprane, the best-selling medicine ...
Sanofi in Talks With French Government to Address Concerns on Opella Deal
Sanofi is in discussions with the French government to address concerns officials raised about a potential sale of a ...